Overview
MetP Pharma specializes in proprietary nasal drug delivery technology for nose-to-brain and nose-to-systemic transport, bypassing the blood-brain barrier for biologics and peptides like GLP-1 agonists such as semaglutide. Their platform features the patented Lecticula mono-dose device, which ensures precise, patient-friendly self-administration independent of head position. Preclinical data demonstrate rapid brain targeting with brain-to-plasma ratios greater than 1, low systemic exposure, and suitability for long-term dosing.
Frequently asked questions
- What is MetP Pharma's core technology?
- MetP Pharma's nasal enabling technology uses a carrier gel and the patented Lecticula mono-dose device for non-invasive, self-administered nose-to-brain delivery of biologics and peptides, bypassing the blood-brain barrier.
- What delivery capabilities does it offer?
- The platform supports rapid CNS exposure for GLP-1 drugs like semaglutide, with preclinical brain-to-plasma ratios >1, dose-dependent targeting, and compatibility with a wide range of molecules including dopamine for conditions like ADHD.
- What are the regulatory and geographic details?
- MetP Pharma AG is based in Switzerland with technology validated by independent global research institutions; their pipeline includes pending intranasal dopamine for ADHD, supported by 67+ publications and patents.